Predictors of mortality in HIV-1 infected children on antiretroviral therapy in Kenya: a prospective cohort

被引:64
|
作者
Wamalwa, Dalton C. [1 ]
Obimbo, Elizabeth M. [1 ]
Farquhar, Carey [2 ,3 ]
Richardson, Barbra A. [4 ]
Mbori-Ngacha, Dorothy A. [1 ]
Inwani, Irene [5 ]
Benki-Nugent, Sara [2 ]
John-Stewart, Grace [2 ,3 ]
机构
[1] Univ Nairobi, Dept Paediat, Nairobi 00202, Kenya
[2] Univ Washington, Dept Epidemiol, Seattle, WA 98104 USA
[3] Univ Washington, Dept Med, Seattle, WA 98104 USA
[4] Univ Washington, Dept Biostat, Seattle, WA 98104 USA
[5] Kenyatta Natl Hosp, Nairobi 00202, Kenya
关键词
HIV-INFECTION; VIRUS;
D O I
10.1186/1471-2431-10-33
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
Background: Among children, early mortality following highly active antiretroviral therapy (HAART) remains high. It is important to define correlates of mortality in order to improve outcome. Methods: HIV-1-infected children aged 18 months-12 years were followed up at Kenyatta National Hospital, Nairobi after initiating NNRTI-based HAART. Cofactors for mortality were determined using multivariate Cox regression models. Results: Between August 2004 and November 2008, 149 children were initiated on HAART of whom 135 were followed for a total of 238 child-years (median 21 months) after HAART initiation. Baseline median CD4% was 6.8% and median HIV-1-RNA was 5.98-log(10) copies/ml. Twenty children (13.4%) died at a median of 35 days post-HAART initiation. Mortality during the entire follow-up period was 8.4 deaths per 100 child-years (46 deaths/100 child-years in first 4 months and 1.0 deaths/100 child-years after 4 months post-HAART initiation). On univariate Cox regression, baseline hemoglobin (Hb) < 9 g/dl, weight-for-height z-score (WHZ) < -2, and WHO clinical stage 4 were associated with increased risk of death (Hb < 9 g/dl HR 3.00 [95% C.I. 1.21-7.39], p = 0.02, WHZ < -2 HR 3.41 [95% C.I. 1.28-9.08], p = 0.01, and WHO clinical stage 4, HR 3.08 [1.17-8.12], p = 0.02). On multivariate analysis Hb < 9 g/dl remained predictive of mortality after controlling for age, baseline CD4%, WHO clinical stage and weight-for-height z-score (HR 2.95 (95% C. I. 1.04-8.35) p = 0.04). Conclusion: High early mortality was observed in this cohort of Kenyan children receiving HAART, and low baseline hemoglobin was an independent risk factor for death.
引用
收藏
页数:8
相关论文
共 50 条
  • [21] Mortality and immunovirological outcomes on antiretroviral therapy in HIV-1 and HIV-2-infected individuals in the Gambia
    Peterson, Ingrid
    Togun, Oluwatoyin
    de Silva, Thushan
    Oko, Francis
    Rowland-Jones, Sarah
    Jaye, Assan
    Peterson, Kevin
    AIDS, 2011, 25 (17) : 2167 - 2175
  • [22] Genotypic Determination of HIV Tropism in a Cohort of Patients Perinatally Infected With HIV-1 and Exposed to Antiretroviral Therapy
    Di Biagio, Antonio
    Parisini, Andrea
    Bruzzone, Bianca
    Prinapori, Roberta
    Lauriola, Marinella
    Paolucci, Stefania
    Signori, Alessio
    Barresi, Renata
    Icardi, Giancarlo
    Calderisi, Silvia
    Meini, Genny
    Dentone, Chiara
    Cenderello, Giovanni
    Guerra, Michele
    Maccabruni, Anna
    Rusconi, Stefano
    Viscoli, Claudio
    HIV CLINICAL TRIALS, 2014, 15 (01): : 45 - 49
  • [23] Heterosexual HIV-1 transmission after initiation of antiretroviral therapy: a prospective cohort analysis
    Donnell, Deborah
    Baeten, Jared M.
    Kiarie, James
    Thomas, Katherine K.
    Stevens, Wendy
    Cohen, Craig R.
    McIntyre, James
    Lingappa, Jairam R.
    Celum, Connie
    LANCET, 2010, 375 (9731): : 2092 - 2098
  • [24] Immunological and Virological Responses to Highly Active Antiretroviral Therapy in HIV-1 Infected Children
    Singh, Ravinder
    Mukherjee, Aparna
    Singla, Mohit
    Das, Bimal Kumar
    Kabra, Sushil Kumar
    Lodha, Rakesh
    INDIAN JOURNAL OF PEDIATRICS, 2017, 84 (12): : 893 - 896
  • [25] Immunological and Virological Responses to Highly Active Antiretroviral Therapy in HIV-1 Infected Children
    Ravinder Singh
    Aparna Mukherjee
    Mohit Singla
    Bimal Kumar Das
    Sushil Kumar Kabra
    Rakesh Lodha
    The Indian Journal of Pediatrics, 2017, 84 : 893 - 896
  • [26] Morbidity and mortality in HIV-infected children on antiretroviral therapy in Togo
    Mouhari-Toure, A.
    Mahamadou, G.
    Kombate, K.
    Akakpo, A. S.
    Teclessou, J. N.
    Singo, A.
    Pitche, P.
    MEDECINE ET SANTE TROPICALES, 2018, 28 (01): : 54 - 60
  • [27] Hearing loss and antiretroviral therapy in patients infected with HIV-1
    Marra, CM
    Wechkin, HA
    Longstreth, WT
    Rees, TS
    Syapin, CL
    Gates, GA
    ARCHIVES OF NEUROLOGY, 1997, 54 (04) : 407 - 410
  • [28] Associations Between Persistent Hiv-1 Viremia On Antiretroviral Therapy And Pulmonary Dysfunction In An Hiv-Infected Cohort
    Michael, H.
    Fitzpatrick, M. E.
    Hong, F. F.
    Kingsley, L.
    Kessinger, C.
    Leo, N.
    McMahon, D.
    Mellors, J. W.
    Morris, A. M.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2016, 193
  • [29] HIV-1 Subtypes and Primary Antiretroviral Resistance Mutations in Antiretroviral Therapy Naive HIV-1 Infected Individuals in Turkey
    Sayan, M.
    Willke, A.
    Ozgunes, N.
    Sargin, F.
    JAPANESE JOURNAL OF INFECTIOUS DISEASES, 2013, 66 (04) : 306 - 311
  • [30] Safety and Effectiveness of Combination Antiretroviral Therapy during the First Year of Treatment in HIV-1 Infected Rwandan Children: A Prospective Study
    Mutwa, Philippe R.
    Boer, Kimberly R.
    Asiimwe-Kateera, Brenda
    Tuyishimire, Diane
    Muganga, Narcisse
    Lange, Joep M. A.
    van de Wijgert, Janneke
    Asiimwe, Anita
    Reiss, Peter
    Geelen, Sibyl P. M.
    PLOS ONE, 2014, 9 (11):